CAIRO: A total of 7,000 Hepatitis C patients who relapsed after treatment will end their new treatment regimen by the end of May, head of the National Committee for Control of Viral Hepatitis Waheed Dous told Youm7 in a Tuesday report.
Patients who have been suffering the disease for years are known to relapse after going through the regimen, more than other patients who began treatment soon after contracting the virus.
The regimen of those who relapsed includes Sovaldi, Daklinza, and Ribavirin in a span of six months; it is expected to be highly successful especially with those who have not reached the stage of liver cirrhosis, Dous said.
The 7,000 people represent the first phase of treatment for relapsed patients, Dous added.
One in 10 of the population aged 15-59 is infected, according to the World Health Organization; the government has embarked on a vigorous campaign to put an end to this high prevalence since 2014.
It has also treated more than 45,000 patients at its expense, Youm7 reported.